Generation of gene-corrected functional osteoclasts from osteopetrotic induced pluripotent stem cells.


Journal

Stem cell research & therapy
ISSN: 1757-6512
Titre abrégé: Stem Cell Res Ther
Pays: England
ID NLM: 101527581

Informations de publication

Date de publication:
15 05 2020
Historique:
received: 20 02 2020
accepted: 30 04 2020
revised: 03 04 2020
entrez: 17 5 2020
pubmed: 18 5 2020
medline: 22 6 2021
Statut: epublish

Résumé

Infantile malignant osteopetrosis (IMO) is an autosomal recessive disorder characterized by non-functional osteoclasts and a fatal outcome early in childhood. About 50% of patients have mutations in the TCIRG1 gene. IMO iPSCs were generated from a patient carrying a homozygous c.11279G>A (IVS18+1) mutation in TCIRG1 and transduced with a lentiviral vector expressing human TCIRG1. Embryoid bodies were generated and differentiated into monocytes. Non-adherent cells were harvested and further differentiated into osteoclasts on bovine bone slices. Release of the bone resorption biomarker CTX-I into the media of gene-corrected osteoclasts was 5-fold higher than that of the uncorrected osteoclasts and 35% of that of control osteoclasts. Bone resorption potential was confirmed by the presence of pits on the bones cultured with gene-corrected osteoclasts, absent in the uncorrected IMO osteoclasts. The disease phenotype was partially corrected in vitro, providing a valuable resource for therapy development for this form of severe osteopetrosis.

Sections du résumé

BACKGROUND
Infantile malignant osteopetrosis (IMO) is an autosomal recessive disorder characterized by non-functional osteoclasts and a fatal outcome early in childhood. About 50% of patients have mutations in the TCIRG1 gene.
METHODS
IMO iPSCs were generated from a patient carrying a homozygous c.11279G>A (IVS18+1) mutation in TCIRG1 and transduced with a lentiviral vector expressing human TCIRG1. Embryoid bodies were generated and differentiated into monocytes. Non-adherent cells were harvested and further differentiated into osteoclasts on bovine bone slices.
RESULTS
Release of the bone resorption biomarker CTX-I into the media of gene-corrected osteoclasts was 5-fold higher than that of the uncorrected osteoclasts and 35% of that of control osteoclasts. Bone resorption potential was confirmed by the presence of pits on the bones cultured with gene-corrected osteoclasts, absent in the uncorrected IMO osteoclasts.
CONCLUSIONS
The disease phenotype was partially corrected in vitro, providing a valuable resource for therapy development for this form of severe osteopetrosis.

Identifiants

pubmed: 32414402
doi: 10.1186/s13287-020-01701-y
pii: 10.1186/s13287-020-01701-y
pmc: PMC7227215
doi:

Substances chimiques

TCIRG1 protein, human 0
Vacuolar Proton-Translocating ATPases EC 3.6.1.-

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

179

Références

J Bone Miner Res. 2010 Jan;25(1):106-13
pubmed: 20091929
PLoS One. 2013 Aug 12;8(8):e71098
pubmed: 23951090
Pediatr Blood Cancer. 2018 Jun;65(6):e27010
pubmed: 29469225
Nucleic Acids Res. 2015 Feb 18;43(3):1577-92
pubmed: 25605798
J Bone Miner Res. 2010 Sep;25(9):2069-77
pubmed: 20568230
Blood. 2007 Jun 15;109(12):5178-85
pubmed: 17332244
J Clin Endocrinol Metab. 2017 Sep 1;102(9):3111-3123
pubmed: 28655174
Curr Gene Ther. 2009 Jun;9(3):150-9
pubmed: 19519360
Bone. 2008 Jan;42(1):19-29
pubmed: 17936098
Transfus Med Hemother. 2017 Jun;44(3):135-142
pubmed: 28626364
Nat Rev Endocrinol. 2013 Sep;9(9):522-36
pubmed: 23877423
Blood. 2002 May 1;99(9):3458-60
pubmed: 11964318
J Bone Joint Surg Am. 2019 Nov 6;101(21):1939-1947
pubmed: 31567691
Hum Mol Genet. 2001 Aug 15;10(17):1767-73
pubmed: 11532986
Stem Cell Res. 2020 Jan;42:101660
pubmed: 31794943
N Engl J Med. 1980 Mar 27;302(13):701-8
pubmed: 6986555
Stem Cell Res. 2016 Jan;16(1):54-8
pubmed: 27345784
J Virol. 2000 Nov;74(22):10778-84
pubmed: 11044122
Stem Cell Res Ther. 2019 Jul 17;10(1):211
pubmed: 31315669
Pediatr Transplant. 1999;3 Suppl 1:102-7
pubmed: 10587979
Stem Cell Reports. 2015 Oct 13;5(4):558-68
pubmed: 26344905
Hum Gene Ther. 2019 Nov;30(11):1395-1404
pubmed: 31179768
Arch Dis Child. 2000 Nov;83(5):449-52
pubmed: 11040159
Hum Gene Ther. 2018 Aug;29(8):938-949
pubmed: 28726516

Auteurs

Xiaojie Xian (X)

Department of Molecular Medicine and Gene Therapy, Lund Strategic Center for Stem Cell Biology, Lund University, BMC A12, 221 84, Lund, Sweden.

Roksana Moraghebi (R)

Department of Molecular Medicine and Gene Therapy, Lund Strategic Center for Stem Cell Biology, Lund University, BMC A12, 221 84, Lund, Sweden.

Henrik Löfvall (H)

Department of Molecular Medicine and Gene Therapy, Lund Strategic Center for Stem Cell Biology, Lund University, BMC A12, 221 84, Lund, Sweden.
Nordic Bioscience, Herlev, Denmark.

Anders Fasth (A)

Department of Pediatrics, Institute of Clinical Sciences, University of Gothenburg, Gothenburg, Sweden.

Kim Henriksen (K)

Nordic Bioscience, Herlev, Denmark.

Johan Richter (J)

Department of Molecular Medicine and Gene Therapy, Lund Strategic Center for Stem Cell Biology, Lund University, BMC A12, 221 84, Lund, Sweden.

Niels-Bjarne Woods (NB)

Department of Molecular Medicine and Gene Therapy, Lund Strategic Center for Stem Cell Biology, Lund University, BMC A12, 221 84, Lund, Sweden.

Ilana Moscatelli (I)

Department of Molecular Medicine and Gene Therapy, Lund Strategic Center for Stem Cell Biology, Lund University, BMC A12, 221 84, Lund, Sweden. Ilana.Moscatelli@med.lu.se.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH